398-90-3

Usage

Uses

Used in Organic Synthesis:
2',5'-Difluoroacetanilide is used as an intermediate in the synthesis of various chemical substances. Its role in the formation of other compounds is crucial, as it can undergo a range of reactions to produce different products.
Used in Pharmaceutical Industry:
2',5'-Difluoroacetanilide is used as a building block in the development of pharmaceutical compounds. Its unique structure and properties make it a valuable component in the creation of new drugs and medications.
Used in Chemical Research:
2',5'-Difluoroacetanilide is employed as a research tool in the field of chemistry. It is used to study the properties and reactions of anilides, contributing to the understanding of their behavior and potential applications.
Used in Material Science:
2',5'-Difluoroacetanilide is utilized in the development of new materials with specific properties. Its incorporation into various compounds can lead to the creation of materials with unique characteristics, such as improved stability or enhanced reactivity.

InChI:InChI=1/C8H7F2NO/c1-5(12)11-8-4-6(9)2-3-7(8)10/h2-4H,1H3,(H,11,12)

Upstream product

• 367-30-6 2,5-difluoroaniline 
• 108-24-7 acetic anhydride 
• 364-74-9 1,4-difluoro-2-nitrobenzene 
• 75-36-5 acetyl chloride 

Downstream Products

• 325-59-7 (2,5-difluoro-phenyl)-phenyl-amine 
• 1994-23-6 N-<2,5-difluoro-3-(trifluoromethyl)phenyl>acetamide 
• 114973-35-2 N-<2,5-difluoro-4-(trifluoromethyl)phenyl>acetamide 
• 115591-68-9 N-<3,6-difluoro-2-(trifluoromethyl)phenyl>acetamide 
• 114973-37-4 2,5-difluoro-4-pentafluoroethylacetanilide 
• 114973-39-6 2,5-difluoro-4 heptafluoropropylacetanilide 
• 1019585-90-0 2,5-difluorophenylethylamine 
• 1374780-52-5 N,N'-[2,5-bis(4-oxidomorpholin-4-yl)-1,4-phenylene]diacetamide 
• 133531-68-7 1,4-difluoro-2,5-dinitrobenzene 
• 1374780-41-2 4,4'-(2,5-dinitro-1,4-phenylene)dimorpholine 
• 1374780-43-4 1-[2,5-dinitro-4-(pyrrolidin-1-yl)phenyl]piperidine 
• 1374780-44-5 N,N'-[2,5-di(morpholin-4-yl)-1,4-phenylene]diacetamide 
• 1374780-46-7 N,N'-[2-(piperidin-1-yl)-5-(pyrrolidin-1-yl)-1,4-phenylene]diacetamide 
• 366-53-0 N-(2,5-difluoro-4-nitrophenyl)-acetamide 

Relevant academic research and scientific papers

COLLECTIONS OF PEPTIDES, PEPTIDE AGENTS, AND METHODS OF USE THEREOF

The present disclosure provides powerful technologies for the development, production, characterization, and/or use of stapled peptide compositions. Among other things, the present disclosure provides strategies for defining amino acid sequences particularly amenable or useful for stapling, as well as technologies, reagents, and systems for developing, producing, characterizing, and/or using stapled peptides having such amino acid sequences.

2,5-DISUBSTITUTED-1,4-DIAMINOBENZENES

Asymmetrical 2,5-disubstituted-1,4-diaminobenzenes are provided, along with a process for forming both symmetrical and asymmetrical 2,5-disubstituted-1,4-diaminobenzenes.

Synthesis and toxicity of new ring-fused imidazo[5,4-f] benzimidazolequinones and mechanism using amine N-oxide cyclizations

A new synthetic route to ring-fused imidazo[5,4-f]benzimidazoles is reported that can be used to access symmetrical and unsymmetrical quinone anticancer agents. Oxone in formic acid allows cyclisation of o-tert-aminoacetanilides to give ring-fused benzimi

Pyrano-[2,3b]-pyridines as potassium channel antagonists

The design and synthesis of a series of highly functionalized pyrano-[2,3b]-pyridines is described. These compounds were assayed for their ability to block the IKur channel encoded by the gene hKV1.5 in patch-clamped L-929 cells. Six of the compounds in this series showed sub-micromolar activity, the most potent being 4-(4-ethyl-benzenesulfonylamino)-3-hydroxy-2,2-dimethyl-3,4-dihydro-2H-pyrano[2,3b]-pyridine-6-carboxylic acid ethyl-phenyl-amide with an IC50 of 378 nM.

Discovery of 3-[(4,5,7-trifluorobenzothiazol-2-yl)methyl]indole-N-acetic acid (lidorestat) and congeners as highly potent and selective inhibitors of aldose reductase for treatment of chronic diabetic complications

Recent efforts to identify treatments for chronic diabetic complications have resulted in the discovery of a novel series of highly potent and selective 3-[(benzothiazol-2-yl)methyl]indole-N-alkanoic acid aldose reductase inhibitors. The lead candidate, 3-[(4,5,7-trifluorobenzothiazol-2-yl)methyl]indole-N-acetic acid (lidorestat, 9) inhibits aldose reductase with an IC50 of 5 nM, while being 5400 times less active against aldehyde reductase, a related enzyme involved in the detoxification of reactive aldehydes. It lowers nerve and lens sorbitol levels with ED50's of 1.9 and 4.5 mg/kg/d po, respectively, in the 5-day STZ-induced diabetic rat model. In a 3-month diabetic intervention model (1 month of diabetes followed by 2 months of drug treatment at 5 mg/kg/d po), it normalizes polyols and reduces the motor nerve conduction velocity deficit by 59% relative to diabetic controls. It has a favorable pharmacokinetic profile (F, 82%; t1/2, 5.6 h; Vd, 0.694 L/kg) with good drug penetration in target tissues (Cmax in sciatic nerve and eye are 2.36 and 1.45 μg equiv/g, respectively, when dosed with [14C] lidorestat at 10 mg/kg po).

Condensed heterocyclic derivatives and herbicides

A condensed heterocyclic derivative having the formula: STR1 wherein X is an oxygen atom or a sulfur atom; and Z is STR2